Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy

NCT01828762 is registered in ClinicalTrials.gov with Shanghai AbelZeta Ltd. as lead sponsor.

NCT NCT01828762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01828762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
Lead sponsor
Shanghai AbelZeta Ltd.
Phase
Not applicable
Overall status
Completed
Start date
December 31, 2012
Completion date
Not reported
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary hepatocellular carcinoma